Is There a Gender Difference of Metabolic Syndrome in Hemodialysis?


The prevalence of metabolic syndrome is high in hemodialysis. MS is defined by the combination of high blood pressure, dyslipidemia, central obesity and a state of insulin resistance. The aim of this work is to see if there’s a difference by gender in the different parameters of metabolic syndrome and in cardiovascular morbidity in our hemodialysis patients. It is a cross-sectional study of 120 patients older than 18 years on hemodialysis. The metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). A comparison by gender was performed for the following parameters: age, diabetes, hypertension, obesity, dyslipidemia, coronary artery disease and heart failure. Forty chronic hemodialysis patients with metabolic syndrome have been the subject of this study. The sex ratio was 1.88 and the mean age was 55.97 years. Seventy percent had diabetes and 90% were hypertensive. Coronary artery disease was present in 57.5% of cases and heart failure in 52.5% of cases. The study by gender showed no significant difference except for the prevalence of hyper LDL cholesterol. There is a high prevalence of cardiovascular complications in men but a significant difference by gender could not be demonstrated.

Share and Cite:

Gorsane, I. , Mahfoudhi, M. , El Euch, M. , Younsi, F. and Abdallah, T. (2015) Is There a Gender Difference of Metabolic Syndrome in Hemodialysis?. International Journal of Clinical Medicine, 6, 711-715. doi: 10.4236/ijcm.2015.610094.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Prasad, G.V. (2014) Metabolic Syndrome and Chronic Kidney Disease: Current Status and Future Directions. World Journal of Nephrology, 3, 210-219.
[2] Kubrusly, M., Oliveira, C.M., Simoes, P.S., Lima, R.O., Galdino, P.N., Sousa, P.A., et al. (2015) Prevalence of Metabolic Syndrome According to NCEP-ATP III and IDF Criteria in Patients on Hemodialysis. Jornal Brasileiro de Nefrologia, 37, 72-78.
[3] Rasic-Milutinovic, Z., Perunicic, G., Pljesa, S., Gluvic, Z., Ilic, M. and Stokic, E. (2007) Metabolic Syndrome in HD Patients: Association with Body Composition, Nutritional Status, Inflammation and Serum Iron. Internal Medicine, 46, 945-951.
[4] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III). JAMA, 285, 2486-2497.
[5] Hsu, C.Y., McCulloch, C.E., Iribarren, C., Darbinian, J. and Go, A.S. (2006) Body Mass Index and Risk for End-Stage Renal Disease. Annals of Internal Medicine, 144, 21-28.
[6] Bakker, S.L., Gansevoort, R.T. and Zeeuw, D.D. (2007) Metabolic Syndrome: A Fata Morgana? Nephrology Dialysis Transplantation, 22, 15-20.
[7] Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., et al. (2001) Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome. Diabetes Care, 24, 683-689.
[8] Lakka, H.M., Laaksonen, D.E., Lakka, T., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., et al. (2002) The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-Aged Men. JAMA, 288, 2709-2716.
[9] Chen, H.H., Wu, C.J., Chen, Y.C., Tsai, C.S., Lin, F.J. and Yeh, H.I. (2006) Metabolic Syndrome Is Associated with Severe Coronary Artery Disease and Poor Cardiac Outcome in End-Stage Renal Disease Patients with Acute Coronary Syndrome. Coronary Artery Disease, 17, 593-596.
[10] Yang, S.Y., Chiang, C.K., Hsu, S.P., Peng, Y.S., Pai, M.F., Ho, T.I., et al. (2007) Metabolic Syndrome Predicts Hospitalization in Hemodialysis Patients: A Prospective Asian Cohort Study. Blood Purification, 25, 252-259.
[11] Shahrokh, S., Heydarian, P., Ahmadi, F., Saddadi, F. and Razeghi, E. (2012) Association of Inflammatory Biomarkers with Metabolic Syndrome in Hemodialysis Patients. Renal Failure, 34, 1109-1113.
[12] Haffner, S.M., Valdez, R.A., Hazuda, H.P., Mitchell, B.D., Morales, P.A. and Stern, M.P. (1992) Prospective Analysis of the Insulin-Resistance Syndrome (Syndrome X). Diabetes, 41, 715-722.
[13] Ford, E.S. (2005) Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated with the Metabolic Syndrome: A Summary of the Evidence. Diabetes Care, 28, 1769-1778.
[14] Park, J.T., Chang, T.I., Kim, D.K., Lee, J.E., Choi, H.Y., Kim, H.W., et al. (2010) Metabolic Syndrome Predicts Mortality in Non-Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis. Nephrology Dialysis Transplantation, 25, 599-604.
[15] Tu, S.F., Chou, Y.C., Sun, C.A., Hsueh, S.C. and Yang, T. (2012) The Prevalence of Metabolic Syndrome and Factors Associated with Quality of Dialysis among Hemodialysis Patients in Southern Taiwan. Global Journal of Health Science, 4, 53-62.
[16] Frohlich, M., Imhof, A., Berg, G., Hutchinson, W.L., Pepys, M.B., Boeing, H., et al. (2000) Association between C-Reactive Protein and Features of the Metabolic Syndrome: A Population-Based Study. Diabetes Care, 23, 1835-1839.
[17] Jofre, R., Rodriguez-Benitez, P., Lopez-Gomez, J.M. and Pérez-Garcia, R. (2006) Inflammatory Syndrome in Patients on Hemodialysis. Journal of the American Society of Nephrology, 17, S274-S280.
[18] Ridker, P.M., Buring, J.E., Cook, N.R. and Rifai, N. (2003) C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events. Circulation, 107, 391-397.
[19] Kalantar-Zadeh, K., Block, G., Humphreys, M.H. and Kopple, J.D. (2003) Reverse Epidemiology of Cardiovascular Risk Factors in Maintenance Dialysis Patients. Kidney International, 63, 793-808.
[20] Al Saran, K., Elsayed, S., Sabry, A. and Hamada, M. (2011) Obesity and Metabolic Syndrome in Hemodialysis Patients: Single Center Experience. Saudi Journal of Kidney Diseases and Transplantation, 22, 1193-1198.
[21] Xie, Q., Zhang, A.H., Chen, S.Y., Lai, X., Zhang, F., He, L., et al. (2012) Metabolic Syndrome Is Associated with Better Nutritional Status, but Not with Cardiovascular Disease or All-Cause Mortality in Patients on Haemodialysis. Archives of Cardiovascular Diseases, 105, 211-217.
[22] Stolic, R.V., Trajkovic, G.Z., Peric, V.M., Stolic, D.Z., Sovtic, S.R., Aleksandar, J.N., et al. (2010) Impact of Metabolic Syndrome and Malnutrition on Mortality in Chronic Hemodialysis Patients. Journal of Renal Nutrition, 20, 38-43.
[23] Despres, J.P. and Lemieux, I. (2006) Abdominal Obesity and Metabolic Syndrome. Nature, 444, 881-887.
[24] Tsai, J.P., Tsai, C.C., Liu, H.M., Lee, C.J., Liou, H.H. and Hsu, B.G. (2011) Hyperleptinaemia Positively Correlated with Metabolic Syndrome in Hemodialysis Patients. European Journal of Internal Medicine, 22, e105-e109.
[25] Tsai, J.P., Liou, H.H., Liu, H.M., Lee, C., Lee, R. and Hsu, B.G. (2010) Fasting Serum Fatty Acid-Binding Protein 4 Level Positively Correlates with Metabolic Syndrome in Hemodialysis Patients. Archives of Medical Research, 41, 536-540.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.